相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Use of Rifaximin in Patients With Cirrhosis
Paolo Caraceni et al.
HEPATOLOGY (2021)
Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States
Michael L. Volk et al.
JOURNAL OF MEDICAL ECONOMICS (2021)
Rapid metabolic and bioenergetic adaptations of astrocytes under hyperammonemia - a novel perspective on hepatic encephalopathy
Marcel Zimmermann et al.
BIOLOGICAL CHEMISTRY (2021)
Rifaximin microbial resistance and its efficacy and safety as a secondary prophylaxis of hepatic encephalopathy in patients with hepatitis C virus-related cirrhosis
Mai Abdel Moneim et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2021)
Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis
Segundo Moran et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2021)
Minimal Hepatic Encephalopathy
Briette Verken Karanfilian et al.
CLINICS IN LIVER DISEASE (2020)
Hepatic encephalopathy: Diagnosis and management
Lorenzo Ridola et al.
JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE (2020)
Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles
Karin Weissenborn
DRUGS (2019)
Chinese guidelines on management of hepatic encephalopathy in cirrhosis
Xiao-Yuan Xu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Minimal Hepatic Encephalopathy in Indians: Psychometric Hepatic Encephalopathy Score and Inhibitory Control Test for Diagnosis and Rifaximin or Lactulose for Its Reversal
Vinay B. Pawar et al.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2019)
Evaluation of the cost-effectiveness of rifaximin-α for the management of patients with hepatic encephalopathy in the United Kingdom
Ellen Berni et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial
Kazuyuki Suzuki et al.
HEPATOLOGY RESEARCH (2018)
Breakthrough Clostridium difficile Infection in Cirrhotic Patients Receiving Rifaximin
Elena Reigadas et al.
CLINICAL INFECTIOUS DISEASES (2018)
Emergence of rifampin-resistant staphylococci after rifaximin administration in cirrhotic patients
Ji Young Chang et al.
PLOS ONE (2017)
Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver
Hendrik Vilstrup et al.
HEPATOLOGY (2014)
Management of Hepatic Encephalopathy in the Hospital
Michael D. Leise et al.
MAYO CLINIC PROCEEDINGS (2014)
Use of Rifamycin Drugs and Development of Infection by Rifamycin-Resistant Strains of Clostridium difficile
Jamie S. Huang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis
Dong Wu et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2013)
Rifaximin Improves Psychometric Performance and Health-Related Quality of Life in Patients With Minimal Hepatic Encephalopathy (The RIME Trial)
Sandeep Singh Sidhu et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Rifaximin intake leads to emergence of rifampin-resistant staphylococci
Thomas Valentin et al.
JOURNAL OF INFECTION (2011)
Rifaximin Treatment in Hepatic Encephalopathy
Nathan M. Bass et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, doubledummy, controlled clinical trial
A Mas et al.
JOURNAL OF HEPATOLOGY (2003)
分享论文
